Real Chemistry

A

AET

Part of the 100% family-owned Tiefenbacher Group, AET provides end-to-end pharmaceutical development and out-licensing solutions spanning more than 80 countries. With over 900 employees and its own laboratories and manufacturing facilities, the group builds efficient supply chains for marketing partners across every major regulated market, removing the full burden of development risk from commercial partners and accelerating their time-to-market. Out-Licensing Model and Core Capabilities AET's business model centres on developing, manufacturing, and registering pharmaceutical products before licensing them to partners worldwide. The portfolio covers value-added generic drug development, innovative medicines, and high-potent compounds, addressing three strategic pillars: better affordability, broader global availability, and genuine therapeutic improvement. From early formulation through regulatory dossier preparation, clinical supply, and multi-market registration, AET manages the entire product life cycle on behalf of its licensing partners. A recognised strength is the organisation's expertise in preparing best-in-class regulatory dossiers that support complex simultaneous launches across multiple jurisdictions. This capability has attracted some of the world's most trusted pharmaceutical brands as long-term partners, underpinned by consistent manufacturing quality and a scalable supply-chain infrastructure that handles both small-molecule and high-potency product categories. The Tiefenbacher Group's integrated model, combining in-house R&D, production, and regulatory affairs under one ownership structure, offers partners a single point of accountability from concept to commercial launch. AET's reach across diverse regulatory environments, from the European Medicines Agency to emerging-market agencies, makes it a capable partner for companies seeking to extend the commercial footprint of established or novel pharmaceutical products. Further information is available at aet.eu.

View profile

T

Trinity Life Sciences

Trinity Life Sciences has built its reputation as one of the most trusted commercial strategy and analytics partners in the life sciences industry, working exclusively with pharmaceutical, biotechnology, and medical device companies to inform critical business decisions across the product lifecycle. Founded in 1996 and headquartered in Waltham, Massachusetts, Trinity operates as a specialised consultancy and analytics firm rather than a drug developer. Its core value lies in helping biopharma clients answer high-stakes commercial questions: whether a therapy will find a viable market, how to price and position it, and how to launch it effectively in competitive or rare-disease settings. The firm's capabilities span market access and pricing strategy, brand and portfolio planning, forecasting, patient analytics, and real-world evidence. It is particularly well regarded for its work in rare diseases and specialty therapeutics, where small patient populations and complex reimbursement landscapes demand highly precise commercial intelligence. Trinity also supports early-stage asset valuation and business development assessments, making it a resource across both pre-launch and in-market phases. Trinity serves a broad client base that includes global pharmaceutical majors, mid-size specialty companies, and emerging biotechs. Its integrated approach, combining primary market research, proprietary data assets, and consulting expertise, differentiates it from pure-play research vendors or strategy firms that lack deep life sciences domain knowledge. Further information is available at trinitylifesciences.com.

View profile

K

Komodo Health

Built on one of the largest repositories of real-world patient data in the United States, Komodo Health helps life sciences companies, payers, and health systems turn complex healthcare information into actionable intelligence. Founded in 2014 and headquartered in San Francisco, California, the company has assembled a longitudinal dataset covering hundreds of millions of patient journeys, drawn from claims, electronic health records, and other clinical sources. The company's flagship platform, the Healthcare Map, sits at the centre of its offering. It models the full continuum of patient experience across disease areas, enabling clients to identify gaps in diagnosis and treatment, understand care pathways, and prioritise commercial or medical strategy with precision. Pharmaceutical manufacturers use Komodo's tools across drug launch planning, real-world evidence generation, patient finding, and competitive intelligence. Komodo Health serves a broad range of therapy areas including oncology, rare disease, neurology, immunology, and cardiovascular conditions, among others. Its analytics products are used by medical affairs, market access, commercial, and health economics teams within its client base. The company also supports payers and provider organisations seeking to improve population health management through data-driven insights. Backed by significant venture investment and operating as a private company, Komodo Health has grown rapidly since its founding and counts many of the world's leading pharmaceutical and biotechnology companies among its clients. Its approach of combining breadth of patient-level data with disease-specific analytical frameworks has positioned it as a recognised name in the real-world data and analytics segment of the life sciences industry. Further information is available at komodohealth.com.

View profile

Real Chemistry

About Real Chemistry

Integrated Health Agency Model

Therapy Areas & Life Sciences Focus

More in Consulting, Advisory & MedComms

List Your Company

Advertise With Us